Chan EY, Webb H, Yu E, et al. - An international, multicenter retrospective study was carried out at 11 tertiary pediatric nephrology centers in Asia, Europe, and North America of children 1-18 years of age with complicated steroid-dependent/ frequently-relapsing nephrotic syndrome receiving rituximab between 2005-2016 for 18 or more months follow-up in order to ascertain the optimal rituximab regimen. Among the 511 children, low, medium and high dose rituximab was given to 191, 208 and 112 children, respectively and 283 received maintenance immunosuppression. Renal biopsies were done in 317 children designating the predominant histology was minimal change disease. Results designated that both rituximab dose, as well as maintenance immunosuppression, had significant impacts on the treatment outcomes.